Denali Therapeutics Inc. (DNLI) compared with its closest peers (CGON, SRRK, ADPT, IOVA, RLAY). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| CG Oncology, Inc. Common stock (CGON) | $6.88B | -20.0 |
| Scholar Rock Holding Corporation (SRRK) | $6.61B | -13.4 |
| Adaptive Biotechnologies Corporation (ADPT) | $4.07B | -41.6 |
| Iovance Biotherapeutics, Inc. (IOVA) | $4.05B | -2.5 |
| Relay Therapeutics, Inc. (RLAY) | $3.78B | -5.3 |
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.08B | -51.6 |
| Beam Therapeutics Inc. (BEAM) | $2.93B | -34.2 |
| Kodiak Sciences Inc. (KOD) | $2.50B | -6.5 |
| BioCryst Pharmaceuticals, Inc. (BCRX) | $2.47B | 6.5 |
| Hemab Therapeutics Holdings, Inc. (COAG) | $2.25B | — |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
DNLI overview · DNLI earnings · DNLI financials · DNLI KPIs · DNLI investor relations · DNLI ownership · DNLI filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.